SYSTEMS 2 (L160) A Randomised Phase II trial of standard versus dose escalated radiotherapy in the treatment of pain in malignant pleural mesothelioma

Transcription

1 SYSTEMS 2 (L160) A Randomised Phase II trial of standard versus dose escalated radiotherapy in the treatment of pain in malignant pleural mesothelioma ISRCTN No: ISRCTN Protocol No: SYSTEMS Sponsor Ref: GN13ON388 Sponsor/Co Sponsor: NHS Greater Glasgow & Clyde/ University of Glasgow Chief Investigator: Professor Anthony Chalmers Co ordinating CTU: CRUK Clinical Trials Unit, Glasgow INITIATION SLIDES (VERSION 1.0, 14 July 2016)

2 Study Details **Please note this presentation has been prepared as part of your site initiation. These slides are a compliment to the protocol. All site staff must have read and understood the protocol, and the study requirements prior to signing off the initiation acknowledgement sheet.** Study will be conducted according to ICH GCP guidelines E6 Study conducted in accordance with the EU Directive 2001/20/EC & amendments Study carried out in accordance with the World Medical Association Declaration of Helsinki Ethical Principles for Medical Research involving Human Subject 1964 (as amended) Study carried out in accordance to Research Governance Framework

3 Study Organisation The study is being co ordinated via the Cancer Research UK Clinical Trials Unit, Glasgow Sponsor of the study is Greater Glasgow Health Board (GGHB) and University of Glasgow (GU) Chief Investigator is Professor Anthony Chalmers Study is being funded by educational grants from The June Hancock Mesothelioma Research Fund and The Beatson Cancer Charity

4 Study Team Chief Investigator: Professor Anthony Chalmers Clinical Research Fellow: Dr Miranda Ashton Project Manager: Pharmacovigilance: Sponsor Contact: Laura Alexander Lindsey Connery Paul Dearie Clinical Trial Co ordinator: Ann Peek Clinical Trial Monitor: Calum Innes

5 Study Design Design: A multicentre phase II randomised study comparing two schedules of hypofractionated radiotherapy: Dose escalated, 36 Gy in 6# over two weeks (treatment arm) and 20 Gy in 5# over one week (standard arm) Sample Size: The sample size for this study is 112 patients with a histological or multidisciplinary team (MDT) diagnosis of MPM for whom radiotherapy is indicated for pain control Patients will be recruited from 8 10 UK centres and will be identified either at MDT meetings or by clinical oncologists to whom patients have been referred for radiotherapy

6 Study Objectives/Endpoints Objectives: Primary: Establish whether dose escalated, hypo fractionated radiotherapy (36 Gy in 6#) increases the proportion of MPM patients experiencing a clinically significant improvement in pain at 5 weeks compared with standard radiotherapy (20 Gy in 5#) Secondary: Determine the relative effects of dose escalated and standard radiotherapy on: Acute toxicity at end of radiotherapy and weeks 5 and 9 Pain response at weeks 5 and 9 (BPI) Radiological response at week 9, measured by CT scan reported to modified RECIST Overall survival Quality of life at weeks 5 and 9 (EORTC QLQ C30, LC13) Exploratory: Change in strong opioid use between baseline and study endpoint Health related quality of life (HRqol) at week 9, measured by EQ5D and ICECAP SCM Potential predictive biomarkers and response biomarkers including plasma fibulin (optional) Histopathological and immunohistochemical predictive biomarkers (optional)

7 Modified RECIST Reporting Requirements All radiological investigations must be reported as per protocol / modified RECIST Source documentation of this must be available for review if the original report has had to be supplemented to bring it in line with protocol requirements CRUK CTU, Glasgow have produced a worksheet to assist with the documentation of study specific reporting and will make this available to any participating site upon request to the study monitor

8 Eligibility Criteria Inclusion Criteria Histological and/or MDT diagnosis of MPM Performance status 0 2 (ECOG) Predicted life expectancy of >12 weeks CT scan within 8 weeks of starting radiotherapy Worst Pain 4/10 (0 10 Numerical Rating Scale) Ability to provide written informed consent prior to participating in the trial and prior to any trial related procedures being performed Willingness to comply with scheduled visits, treatment plans, laboratory tests and other study procedures Patients must have a radiotherapy plan compatible with the treatment arm (30 36 Gy in 5 6 fractions) Exclusion Criteria Patients who have received anti cancer therapy within the 4 weeks prior to study entry that is likely to alter pain at the index site during the duration of the study. Patients who are planned to have further anti cancer therapy within 6 weeks post radiotherapy treatment Psychotic disorders or cognitive impairment Co existing lung tumours at the time of study entry **Please refer to section 3 of the study protocol for full details of the eligibility criteria for the study (Brief details of the key selection criteria only is detailed on this slide)** Please note there will be no exception to the eligibility requirements at the time of registration/randomisation. Queries in relation to the eligibility criteria should be addressed via contact with the CTU prior to registration/randomisation. Patients are eligible for the trial if all the inclusion criteria are met and none of the exclusion criteria apply.

9 Pre Randomisation Requirements Radiotherapy Planning before Randomisation To avoid bias in radiotherapy treatment planning and target volume delineation, patients will first be registered on to the study; then randomised AFTER completion of radiotherapy planning but prior to receiving the first radiotherapy treatment Radiotherapy plans must be acceptable for the higher dose/fractionation regimen and can be changed to the lower dose regimen if the patient is subsequently randomised to this arm Stabilisation of Pain before Randomisation To enable the effects of the radiotherapy to be determined, patients should have their pain control optimised and their pain stabilised as much as possible before randomisation. Patients should be reviewed by the local palliative care team if necessary Stable pain will be defined as an average pain score at the index site of between 4 and 8 (inclusive, 0 10 Numerical Rating Score) for a minimum of 72 hours prior to randomisation While stable pain is recommended, it is not an absolute inclusion criterion. However, patients whose worst pain score is lower than 4 at Baseline Visit 2 will no longer be eligible for the study

10 Registration & Randomisation Process Registration Check that patient fulfils all the eligibility criteria as per trial protocol Complete Registration Form Site staff must contact the Clinical Trials Unit, Glasgow to register the patient. Registration to the trial can be done by either telephone or fax on the following numbers: Tel no: Fax no: * Monday Thursday Friday, except public holidays * Faxes received outside of office hours will be processed the next working day Each patient registered will be allocated a unique 3 digit sequential patient ID number for the trial Randomisation Check that patient still fulfils all the eligibility criteria and has radiotherapy plan compatible with dose escalated arm (as per trial protocol) Complete Randomisation Form Site staff must contact the Clinical Trials Unit, Glasgow to register the patient using details above Eligible patients will be randomised to either standard or dose escalated radiotherapy Each patient randomised will be allocated a unique sequential patient ID number for the study

11 Study Treatment Details Two schedules of hypo fractionated radiotherapy: Treatment Arm: Dose escalated, 36 Gy delivered in 6 fractions over two weeks OR Standard arm: 20 Gy delivered in 5 fractions over one week **Please refer to study protocol for detailed information on study treatments, including planning and administration of radiotherapy.**

12 Radiotherapy Dose Modifications Radiotherapy Planning For patients with large volume disease or where there is a risk of severe acute toxicity there will be the option of reducing dose to 30 Gy in 5 fractions **Please refer to Appendix 2 of the study protocol for full details of radiotherapy planning** During Radiotherapy Delays in radiotherapy of up to 1 week are permitted If patients experience acute toxicity attributable to radiotherapy during radiotherapy, treatment should be discontinued. If toxicity resolves completely within one week, patients can continue at the same dose, provided measures have been taken to prevent further severe acute toxicity (e.g. antiemetics) **Please refer to section 5.6 of the study protocol for full details of treatment modifications/dose reductions/delays (Brief details in relation to treatment modifications are provided on these slides). **

13 Visit Schedule

14 Informed Consent Process Informed consent process: Two original Consent Forms must be completed by a clinician (or deputy listed on delegation log) Two originals signed and completed by the patient Date must be prior to registration Make one photocopy Original to be filed in Investigator File Original or photocopy to be given to patient (+PIS) Photocopy to be filed in hospital notes Consent Form must not be sent to your coordinating trials office CONSENT WITHDRAWAL This is when the patient specifically asks to withdraw their consent at any point in the study. If this occurs: Document clearly in the patient notes that the patient has withdrawn consent, the level of consent withdrawal and the reason (if the patient has given any) Complete the consent withdrawal notification form Send the consent withdrawal notification form to the CRUK CTU; No further follow up should be collected on the patient from that point onwards.

15 Process for notification of protocol deviations by sites All participating sites must notify the Sponsor (via CRUK CTU) of all deviations from the protocol or GCP immediately The Sponsor requires a report on the incident(s) and a protocol deviation form will be provided during site initiation which should be used for informing of protocol deviations If site staff are unsure whether a certain occurrence constitutes a deviation from the protocol or GCP, the CRUK CTU trial team and Sponsor can be contacted immediately to discuss. The Sponsor will assess all incidents with respect to the criteria of a serious breach

16 Management of Serious Breaches The PI and site staff will be notified of any potential issues that have been identified which are considered to require escalation to the sponsor The CRUK CTU will act as the liaison between the PI and Sponsor to clarify any details or request any further information in relation to the issues Once agreed by the Sponsor that the issues are a potential serious breach or are a serious breach they will prepare the report to the Ethics Committee It is important that sites respond to requests for further information in a timely manner as serious breaches are required to be reported within 7 days of the sponsor becoming aware of issue Sponsor will onwardly report as required The Ethics Committee will respond to Sponsor and further investigation is carried out as appropriate with same staff as outlined above

17 Monitoring plan and visits Monitoring Visits/Schedule: Post initiation Monitor s check call within 10 working days of the site activation Telephone monitoring call one telephone monitoring call to be scheduled after the 1 st patient at each trial site has completed their radiotherapy course. This will be completed no later than 6 weeks post 1 st patient at site completing radiotherapy For cause monitoring visit on site visit to deal with specific issues, if required Closeout monitoring visit Telephone or on site monitoring visit at end of trial Telephone & Remote Monitoring: The time & date will be agreed with a member of the Site Study Team A pro forma covering the questions which will be covered during the telephone monitoring visit will be sent with confirmation of the agreed date Please set aside 50 to 70 minutes for this call On Site Monitoring: All patient source documentation should be made available to enable Source Document Verification by the Clinical Trial Monitor A full working day is required for on site visits & arrangements should be in place to facilitate the monitor access on the agreed date If sites are able to provide printed results/reports these must be filed in the source documents If a site is using electronic data reporting systems or electronic records &hardcopiesarenot available the clinical trial monitor must be permitted access to the system either by being issued with a temporary login or a member of staff available for the duration of the visit to facilitate electronic access to authorised reports/results All findings will be discussed at an end of visit meeting and any unresolved issues raised as Action Points Action Points will be followed up by the monitor until resolved

18 CRFs: The following Case Report Forms will be in use for this study: Registration Form Randomisation Form Pre Treatment Form End of Radiotherapy Visit Week5 and week 9 Follow up CRF Visit 6 Week 26 Follow up CRF QoL ICECAP SQM QoL EORTC QLQC30 L13 Qol EQ 5D Radiotherapy CRF Consent Withdrawal Form Pregnancy Notification Form Patient Transfer Form SAE form Data Management CRF Completion Case Report forms will be supplied electronically and these must be completed in accordance with the CRF and SAE completion guidelines issued with the CRFs. Data Escalation Process: CRUK CTU will regularly chase outstanding data from participating sites. Routine requests for outstanding data and outstanding data queries will be performed quarterly or more regularly if required for a specific study. Sites will be routinely requested to return outstanding data and data queries within 6 weeks of receiving the queries or the CRF being due for completion. Trigger reports will be run quarterly at the same point as the routine requests for data. If any site has 20%of forms overdue for more than 3 months (at least 10 forms meeting this criteria) or any forms greater than 6 months overdue the site will be contacted. A log will be kept of any sites meeting a trigger point. If a site consistently meets a trigger point an escalation process will be begin. See protocol for further information.

19 Site Set up Process CTU Glasgow REC approval Site Initiation Slides Investigator File Pharmacy File Royal Mail Safeboxes Sample Collection Kits SITE SSI (Scotland, England, Northern Ireland) or HRA Approval (England) Delegation Log R&D Approval CVs for Study Team Clinical Trial Agreement GCP Certificates for Study Team PIS, Consent, GP Letter etc on trust headed paper Initiation Process Activation of site Notification by SITE ACTIVATED

20 Confidentiality All information collected during the course of the study will be kept strictly confidential. Information will be held securely on paper and/or electronically at the CRUK CTU. The CRUK CTU will comply with all aspects of the 1998 Data Protection Act and National Health Service Guidelines for storage, transmittal and disclosure of patient information. Data on patients treated on the study will be held in study case report forms (CRFs), these files will be identified by a trial number and patient initials only. Patient identifiable data (such as full name/or initials with date of birth) should not be sent on correspondence. If you need to refer to a patient use trial and patient number. Where central monitoring of source documents by CRUK CTU (or copies of source documents) are required (e.g. scan results of blood results) the personal data of the patients must anonymised on the report e.g. black out the patient s name and any other identifiable information. Where anonymisation of documentation is required, sites are responsible for ensuring no patient identifiable data is present before sending to CRUK CTU.

21 Record Retention and Archiving Arrangements for study Archiving of the trial essential documents should be performed by both the participating trial site and Sponsor/CRUK CTU Participating sites are responsible for archiving their trial related documentation and should follow the requirements of their R&D Office in conjunction with advice from the CRUK CTU and Sponsor regarding the duration of document retention Sites should not archive their trial documentation until they have been instructed by the CRUK CTU or Sponsor that they are able to do so. Where possible, at the time of archiving, sites will be notified of the archiving retention period. If this is not confirmed at the time of archiving, sites should not destroy archived documentation until authorisation is given from the Sponsor The Sponsor and CRUK CTU will be responsible for archiving the Trial Master File (TMF) and all other essential trial documentation that is not held at participating trial sites as per their applicable SOPs

22 Pharmacovigilance Adverse Events (AEs) AEs will be recorded notified, assessed, reported, analysed and managed in accordance with the Medicines for Human Use (Clinical Trials) Regulations 2004 (as amended) and the study protocol Serious Adverse Events (SAEs) Serious Adverse Events (SAEs) must be reported to the Pharmacovigilance Office, CRUK CTU, Glasgow immediately and under no circumstances should this exceed 24 hours. SAEs are required to be reported from the start of radiotherapy treatment up to an including 30 days after the last fraction of radiotherapy. Any SAE that occurs after 30 days post radiotherapy (with no time limit) is also required to be reported if the Investigator thinks the SAE is related to protocol treatment and is medically important **For full details on Safety Reporting please see section 7 of the current study protocol** SAE References For each SAE received for a patient a SAE reference is allocated by CRUK CTU Pharmacovigilance team (for e.g. 1 for first event and 2 for patients second event ) where details of SAE are recorded on the CRF for e.g. Adverse Event table the SAE reference number allocated to the event should be recorded on the CRF. Pharmacovigilance (PV) Data Escalation Process The CRUK CTU Pharmacovigilance team will regularly chase outstanding data from participating sites in relation to SAE report forms with request for data/queries to be returned within a required timeframe. If following requests a response is not received from site staff an escalation process will begin. CRUK CTU Pharmacovigilance Team If sites have any queries they should contact the CRUK CTU Pharmacovigilance Team who will be happy to provide advice. mvls ctu pv@glasgow.ac.uk Telephone number: /7211/7953

23 Radiotherapy QA Radiotherapy Quality Assurance The radiotherapy quality assurance (RT QA) programme for the study will be designed and implemented by the National Radiotherapy Trials QA (RTTQA) Group Pre trial QA Facility questionnaire (FQ) General and trial specific questions on equipment, software and techniques to be used for the trial Dummy run QA of the outlining and planning technique for those centres where QA cannot be streamlined through a previous lung trial Dosimetry audit For IMRT delivery appropriate independent dosimetry audit evidence from centres will be required. Please contact the RTTQA group to discuss On trial QA Data collection for all patients Anonymised data, in DICOM format, will be collected by the QA team for all patients treated in the trial. This may include a brief clinical history, diagnostic imaging, full planning data including; CT images, structure set, plan and dose cube **For full details on RTTQA process please see section and Appendix 2 of the current study protocol**

24 Translational Research Requirements Blood samples Blood samples for research purposes at the Baseline visit and at weeks 5 and 9 Archival Tissue Samples Collection of surplus diagnostic tissue from the patients original biopsy (if available) for research purposes (additional biopsies or tissue samples will not be required) Consent Consent for translational research is optional. If patients do not consent to providing blood or tissue samples, it will not affect their care and they will still be eligible to participate in SYSTEMS 2 **For full details on handling, processing and shipment of these samples please see the current study Lab Manual**

25 Other Staff The Principal Investigator has overall responsibility for the conduct of the clinical trial at the trial site. BUT All staff must comply with GCP. Staff should only perform tasks delegated to them. Staff should ensure that their details are available to the Investigator. Staff should maintain appropriate confidentiality at all times

26 Contact Details for CRUK CTU, Glasgow Laura Alexander Ann Peak Project Manager Trial Coordinator Tel: Tel: Fax: Fax: E mail: laura.alexander@glasgow.ac.uk E mail: ann.peek@glasgow.ac.uk Calum Innes Trial Monitor Tel: Fax: E mail: calum.innes@glasgow.ac.uk CRUK CTU, Glasgow Cancer Research UK Clinical Trials Office Level 0, Beatson West of Scotland Cancer Centre 1053 Great Western Road Glasgow G12 0YN